Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PYXS Pyxis Oncology Inc
- Stocks
- Healthcare
- NASDAQ: PYXS
Price (delayed)
$1.105
Market cap
$68.45M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.58
Enterprise value
$74.06M
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype
Highlights
Pyxis Oncology's debt has decreased by 4.5% YoY
PYXS's quick ratio is down by 37% year-on-year but it is up by 2.1% since the previous quarter
Pyxis Oncology's revenue has plunged by 100% from the previous quarter and by 100% YoY
Pyxis Oncology's gross profit has shrunk by 100% QoQ and by 100% YoY
Key stats
What are the main financial stats of PYXS
Market
Valuations
Earnings
Shares outstanding
61.95M
Market cap
$68.45M
Enterprise value
$74.06M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.66
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$106.77M
Net income
-$95.23M
EBIT
-$97.4M
EBITDA
-$94.25M
Free cash flow
-$59.5M
Per share
Balance sheet
Liquidity
EPS
-$1.58
EPS diluted
-$1.58
Free cash flow per share
-$0.97
Book value per share
$1.67
Revenue per share
$0
TBVPS
$2.18
Total assets
$135.87M
Total liabilities
$32.76M
Debt
$19.84M
Equity
$103.1M
Working capital
$97.44M
Debt to equity
0.19
Current ratio
7.75
Quick ratio
7.41
Net debt/EBITDA
-0.06
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-54.7%
Return on equity
-69.6%
Return on invested capital
-67%
Return on capital employed
-80.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PYXS stock price
How has the Pyxis Oncology stock price performed over time
Intraday
0.45%
1 week
-8.68%
1 month
-8.68%
1 year
-66.62%
YTD
-29.17%
QTD
12.77%
Financial performance
How have Pyxis Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$106.77M
Net income
-$95.23M
Gross margin
N/A
Net margin
N/A
Pyxis Oncology's revenue has plunged by 100% from the previous quarter and by 100% YoY
Pyxis Oncology's gross profit has shrunk by 100% QoQ and by 100% YoY
Pyxis Oncology's net income has shrunk by 65% YoY and by 23% QoQ
The operating income has plunged by 60% YoY and by 19% from the previous quarter
Price vs fundamentals
How does PYXS's price correlate with its fundamentals
Growth
What is Pyxis Oncology's growth rate over time
Valuation
What is Pyxis Oncology stock price valuation
P/E
N/A
P/B
0.66
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
PYXS's EPS is down by 20% since the previous quarter and by 16% year-on-year
The equity has contracted by 44% YoY and by 15% from the previous quarter
PYXS's P/B is 34% below its last 4 quarters average of 1.0
Pyxis Oncology's revenue has plunged by 100% from the previous quarter and by 100% YoY
Efficiency
How efficient is Pyxis Oncology business performance
Pyxis Oncology's ROA has plunged by 79% YoY and by 38% from the previous quarter
The return on equity has dropped by 78% year-on-year and by 41% since the previous quarter
The ROIC has plunged by 76% YoY and by 33% from the previous quarter
Dividends
What is PYXS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PYXS.
Financial health
How did Pyxis Oncology financials performed over time
The company's total assets fell by 38% YoY and by 14% QoQ
PYXS's quick ratio is down by 37% year-on-year but it is up by 2.1% since the previous quarter
Pyxis Oncology's debt is 81% lower than its equity
The debt to equity has surged by 73% year-on-year and by 12% since the previous quarter
The equity has contracted by 44% YoY and by 15% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.